Unknown

Dataset Information

0

Microtubule-Stabilizing 1,2,4-Triazolo[1,5-a]pyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure-Activity Insights.


ABSTRACT: Microtubule (MT)-stabilizing 1,2,4-triazolo[1,5-a]pyrimidines (TPDs) hold promise as candidate therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions. However, depending on the choice of substituents around the TPD core, these compounds can elicit markedly different cellular phenotypes that likely arise from the interaction of TPD congeners with either one or two spatially distinct binding sites within tubulin heterodimers (i.e., the seventh site and the vinca site). In the present study, we report the design, synthesis, and evaluation of a series of new TPD congeners, as well as matched molecular pair analyses and computational studies, that further elucidate the structure-activity relationships of MT-active TPDs. These studies led to the identification of novel MT-normalizing TPD candidates that exhibit favorable ADME-PK, including brain penetration and oral bioavailability, as well as brain pharmacodynamic activity.

SUBMITTER: Alle T 

PROVIDER: S-EPMC9841533 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Microtubule-Stabilizing 1,2,4-Triazolo[1,5-<i>a</i>]pyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure-Activity Insights.

Alle Thibault T   Varricchio Carmine C   Yao Yuemang Y   Lucero Bobby B   Nzou Goodwell G   Demuro Stefania S   Muench Megan M   Vuong Khoa D KD   Oukoloff Killian K   Cornec Anne-Sophie AS   Francisco Karol R KR   Caffrey Conor R CR   Lee Virginia M-Y VM   Smith Amos B AB   Brancale Andrea A   Brunden Kurt R KR   Ballatore Carlo C  

Journal of medicinal chemistry 20221219 1


Microtubule (MT)-stabilizing 1,2,4-triazolo[1,5-<i>a</i>]pyrimidines (TPDs) hold promise as candidate therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions. However, depending on the choice of substituents around the TPD core, these compounds can elicit markedly different cellular phenotypes that likely arise from the interaction of TPD congeners with either one or two spatially distinct binding sites within tubulin heterodimers (<i>i.e.</i>, the seventh site and the v  ...[more]

Similar Datasets

| S-EPMC6394845 | biostudies-literature
| S-EPMC4076391 | biostudies-literature
| S-EPMC3151920 | biostudies-literature